** Shanghai Henlius Biotech 2696.HK soars 10.8% to HK$20.50; set for biggest one-day pct gain since June 25, 2024
** Stock hits highest since January 14; on course for fifth straight session of gains
** Biopharmaceuticals products maker grants India-based Dr. Reddy's Laboratories SA REDY.NS license to develop, manufacture and commercialise HLX15 in the U.S. and 42 European countries, including the UK and Switzerland, as it deepens overseas expansion
** Says Dr. Reddy's will pay $33 mln upfront and milestone payments of up to $98.6 mln in total and royalties of up to 8% of annual net sales
** HLX15 is used to treat multiple myeloma
** REDY up 0.1%; set for fourth straight session of gains
** Shanghai Henlius's stock soared 70.5% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。